Monomer-Coated Very Small Superparamagnetic Iron Oxide Particles as Contrast Medium for Magnetic Resonance Imaging: Preclinical In Vivo Characterization

Wagner S, Schnorr J, Pilgrimm H, et al. Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization. Invest Radiol 2002;37:167–177. rationale and objectives. Preclinical in-vivo characterization of a newly developed MR contrast medium consisting of very small superparamagnetic iron oxide particles (VSOP) coated with citrate (VSOP-C184). methods. VSOP-C184 (core diameter: 4 nm; total diameter: 8.6 nm; relaxivities in water at 0.94 T (T1) 20.1 and (T2) 37.1 l/[mmol*sec]) was investigated to determine its pharmacokinetics, efficacy, acute single dose toxicity, repeated dose toxicity, and genotoxicity. results. The plasma elimination half-life at 0.045 mmol Fe/kg was 21.3 ± 5.5 minutes in rats and 36.1 ± 4.2 minutes in pigs, resulting in a T1-relaxation time of plasma of < 100 milliseconds for 30 minutes in pigs. The particles are mainly cleared via the phagocytosing system of the liver. MR angiography at a dose of 0.045 mmol Fe/kg shows an excellent depiction of the thoracic and abdominal vasculature in rats and of the coronary arteries in pigs. The LD50 in mice is > 17.9 mmol Fe/kg. A good tolerance and safety profile was found. conclusions. The experiments indicate, that VSOP-C184 may be a well tolerated and safe contrast medium for MR imaging that can be effectively used for MR angiography including visualization of the coronary arteries.

[1]  M. Taupitz,et al.  Intravenous MR lymphography with superparamagnetic iron oxide particles: experimental studies in rats and rabbits , 1995, European Radiology.

[2]  B. Hamm,et al.  Coronary MR angiography: experimental results with a monomer-stabilized blood pool contrast medium. , 2002, Radiology.

[3]  Debiao Li,et al.  Contrast-enhanced MR imaging of coronary arteries: comparison of intra- and extravascular contrast agents in swine. , 2001, Radiology.

[4]  F. Lazeyras,et al.  Detection of Experimental Hepatic Tumors Using Long Circulating Superparamagnetic Particles , 2001, Investigative radiology.

[5]  B Hamm,et al.  New generation of monomer‐stabilized very small superparamagnetic iron oxide particles (VSOP) as contrast medium for MR angiography: Preclinical results in rats and rabbits , 2000, Journal of magnetic resonance imaging : JMRI.

[6]  B. Hamm,et al.  Age‐related blood half‐life of particulate contrast material: Experimental results with a USPIO in rats , 2000, Journal of magnetic resonance imaging : JMRI.

[7]  W. Krause,et al.  Prevention of the hemodynamic effects of iopromide-carrying liposomes in rats and pigs. , 2000, Investigative radiology.

[8]  S. Schmitz,et al.  Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. , 2000, Investigative radiology.

[9]  T. Helbich,et al.  A new polysaccharide macromolecular contrast agent for MR imaging: Biodistribution and imaging characteristics , 2000, Journal of magnetic resonance imaging : JMRI.

[10]  René M. Botnar,et al.  Contrast agent‐enhanced, free‐breathing, three‐dimensional coronary magnetic resonance angiography , 1999, Journal of magnetic resonance imaging : JMRI.

[11]  RES‐specific imaging of the liver and spleen with iron oxide particles designed for blood pool MR‐angiography , 1999, Journal of magnetic resonance imaging : JMRI.

[12]  A. Ragnarsson,et al.  Pulmonary MR angiography with ultrasmall superparamagnetic iron oxide particles as a blood pool agent and a navigator echo for respiratory gating: pilot study. , 1999, Radiology.

[13]  R Weissleder,et al.  MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. , 1999, AJR. American journal of roentgenology.

[14]  C. Lorenz,et al.  Benefit of T1 reduction for magnetic resonance coronary angiography: A numerical simulation and phantom study , 1999, Journal of magnetic resonance imaging : JMRI.

[15]  J Keegan,et al.  Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography , 1999, Journal of magnetic resonance imaging : JMRI.

[16]  J. Brain,et al.  Pulmonary intravascular macrophages: their contribution to the mononuclear phagocyte system in 13 species. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[17]  T L Chenevert,et al.  Magnetic resonance angiography with gadomer-17. An animal study original investigation. , 1998, Investigative radiology.

[18]  R. Felix,et al.  Differences in predominant enhancement mechanisms of superparamagnetic iron oxide and ultrasmall superparamagnetic iron oxide for contrast-enhanced portal magnetic resonance angiography. Preliminary results of an animal study original investigation. , 1998, Investigative radiology.

[19]  C. Higgins,et al.  Value of blood pool contrast agents in magnetic resonance angiography of the pelvis and lower extremities , 1998, European Radiology.

[20]  R. Dolan,et al.  Three‐dimensional MRI of coronary arteries using an intravascular contrast agent , 1998, Magnetic resonance in medicine.

[21]  Emmanuelle Canet,et al.  Contrast‐enhanced 3D‐TOF MRA of peripheral vessels: Intravascular versus extracellular MR contrast media , 1998, Journal of magnetic resonance imaging : JMRI.

[22]  R. Dolan,et al.  MS-325: albumin-targeted contrast agent for MR angiography. , 1998, Radiology.

[23]  Application of superparamagnetic iron oxide (AMI-227) for 3D phase-contrast MR angiography. , 1998, Academic radiology.

[24]  Yoshimi Anzai,et al.  MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent , 1997, Journal of magnetic resonance imaging : JMRI.

[25]  B. Bonnemain,et al.  Superparamagnetic nanoparticles as blood-pool contrast agents. Contribution to MRI preclinical investigations. , 1995, Der Radiologe.

[26]  M. Prince,et al.  Gadolinium-enhanced magnetic resonance angiography of abdominal aortic aneurysms. , 1995, Journal of vascular surgery.

[27]  R. Felix,et al.  Gd‐DTPA‐polylysine—enhanced pulmonary time‐of‐flight MR angiography , 1994, Journal of magnetic resonance imaging : JMRI.

[28]  A. Olukotun,et al.  Phase I clinical evaluation of a new iron oxide MR contrast agent , 1994, Journal of magnetic resonance imaging : JMRI.

[29]  P C Lauterbur,et al.  Dendrimer‐based metal chelates: A new class of magnetic resonance imaging contrast agents , 1994, Magnetic resonance in medicine.

[30]  J A Frank,et al.  Frequency dependence of MR relaxation times II. Iron oxides , 1993, Journal of magnetic resonance imaging : JMRI.

[31]  R Weissleder,et al.  A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies. , 1993, Radiology.

[32]  R. Weissleder,et al.  MION-ASF: biokinetics of an MR receptor agent. , 1993, Magnetic resonance imaging.

[33]  R. Weissleder,et al.  Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. , 1990, Radiology.

[34]  M. Moseley,et al.  Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool and perfusion imaging. , 1990, Acta radiologica. Supplementum.

[35]  R Weissleder,et al.  Superparamagnetic iron oxide: pharmacokinetics and toxicity. , 1989, AJR. American journal of roentgenology.

[36]  R Weissleder,et al.  Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging. , 1988, Radiology.

[37]  R Weissleder,et al.  Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. , 1988, Radiology.

[38]  C. Compton,et al.  Ferrite particles: a new magnetic resonance imaging contrast agent. Lack of acute or chronic hepatotoxicity after intravenous administration. , 1987, The Journal of laboratory and clinical medicine.

[39]  T J Brady,et al.  Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. , 1987, Radiology.

[40]  B. Ames,et al.  Revised methods for the Salmonella mutagenicity test. , 1983, Mutation research.

[41]  B. Ames,et al.  Identifying environmental chemicals causing mutations and cancer. , 1979, Science.

[42]  W Schmid,et al.  The micronucleus test. , 1975, Mutation research.

[43]  W. Schmid,et al.  The micronucleus test. Methodological aspects. , 1973, Mutation research.